Pharmaceuticals · COHANCE
Pharma - API & CRAMS
from 429 today
Cohance Lifesciences' Q1FY27 performance was sub-par, marred by the lumpy nature of the CDMO business, high-cost base, and mounting losses of NJ Bio. We cut FY27/28E earnings and maintain REDUCE with a lower target price of INR 365.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
